Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Eye Melanoma Market Size Forecast: How Big Could The Market Get By 2030?
The eye melanoma market has observed robust expansion in recent years. The market is anticipated to expand from $9.86 billion in 2025 to $10.69 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.4%. This historical growth can be linked to improvements in ocular imaging technologies, rising cancer awareness, the proliferation of oncology treatment facilities, advancements in diagnostic capabilities, and better survival outcomes.
The eye melanoma market size is anticipated to experience robust expansion over the next few years. It is projected to reach $15.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.1%. This growth during the forecast period can be attributed to several factors, including the development of innovative immunotherapies, increasing adoption of precision oncology, an expansion in genetic testing, rising investment in rare cancer research, and improvements in early screening programs. Significant trends anticipated for the forecast period involve a heightened focus on early cancer detection, a growing embrace of targeted and immunotherapies, increased utilization of advanced ocular imaging, the expansion of specialized oncology centers, and growing clinical research dedicated to rare eye cancers.
Get A Free Sample Report With In-Depth Market Insights:
Eye Melanoma Market Development Factors: What’s Supporting Demand?
The escalating incidence of eye cancer is anticipated to propel the growth of the eye melanoma market in the forthcoming period. Eye cancer is characterized by the abnormal and unchecked proliferation of cells within the eye’s structures. The expanding recognition and successful handling of early cases are fostering a greater need for specialized therapies and interventions, driven by enhanced detection methods, increased awareness, and advances in treatment approaches. For instance, in 2025, according to the American Cancer Society, a US-based non-profit organization, there were approximately 3,140 new cases of eye and orbital cancers (mainly melanomas), including 1,620 in males and 1,520 in females. Furthermore, there were about 490 deaths from these cancers, comprising 270 males and 220 females. Therefore, the rising prevalence of eye cancer will further drive the expansion of the eye melanoma market.
Eye Melanoma Market Segment Performance And Emerging Opportunities
The eye melanoma market covered in this report is segmented –
1) By Site: Uvea, Sclera, Retina
2) By Diagnosis: Imaging, Biopsy, Eye Exam
3) By Treatment: Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Other Treatment
4) By End User: Hospitals And Clinics, Academic Institutes
Subsegments:
1) By Uvea: Choroid Melanoma, Ciliary Body Melanoma, Iris Melanoma
2) By Sclera: Episcleral Melanoma, Scleral Surface Melanoma, Conjunctival Melanoma
3) By Retina: Macular Melanoma, Peripheral Retinal Melanoma, Optic Disc Melanoma
Eye Melanoma Market Trends Powering Strategic Industry Growth
Prominent companies operating in the eye melanoma market are prioritizing the development of technological advancements, such as protein-kinase C (PKC) inhibitors, to fulfill the growing demand for effective, eye-preserving systemic treatments. PKC inhibitors function as small-molecule agents that specifically obstruct PKC enzymes linked to tumor growth, thereby providing a non-surgical alternative to established therapies like plaque brachytherapy or enucleation. For instance, in March 2025, IDEAYA Biosciences, a US-based precision oncology company, introduced darovasertib, a pioneering first-in-class PKC inhibitor tailored for uveal melanoma. This therapy targets PKC isoforms involved in tumor proliferation, exhibiting tumor shrinkage rates of approximately 82% and eye-preservation rates of 61% in its Phase 2 trials. Darovasertib can be administered to patients eligible for either enucleation or plaque brachytherapy, presenting a systemic, eye-sparing treatment option for primary uveal melanoma.
Eye Melanoma Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the eye melanoma market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Amgen Inc., Castle Biosciences Inc., IDEAYA Biosciences Inc., Delcath Systems Inc., Immunocore Holdings plc, Aura Biosciences Inc., TriSalus Life Sciences Inc., Replimune Group Inc., Linnaeus Therapeutics, iOnctura, LES LABORATOIRES SERVIER, Immatics NV
View The Full Eye Melanoma Market Report:
Eye Melanoma Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the eye melanoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eye melanoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
